Online-Delivered Comprehensive Behavioral Intervention for Tics-Enhanced (CBIT-E)
NCT ID: NCT05050734
Last Updated: 2021-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2021-09-15
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Children randomized to the waitlist control (WLC) will not receive treatment during the 11-week period. Instead, they will be placed on a waitlist to receive standard CBIT following the end of the study period. Participants in this group will complete a screening visit, baseline assessment, and a final assessment, which will occur approximately 11 weeks after baseline.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of an Online Comprehensive Behavioral Intervention for Tics (CBIT) Therapist Training Program
NCT05547854
Comprehensive Behavioral Intervention for Tics
NCT05370391
VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02247206
Dissemination of Comprehensive Behavioral Intervention for Tics (CBIT) to Occupational Therapists: A Feasibility Study
NCT02114905
Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)
NCT02900144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CBIT-E
For those randomized to CBIT-E, treatment will be administered according to the standard CBIT manual, which includes psychoeducation, functional assessment/interventions, habit reversal training, relaxation techniques, and a motivational reward program. However, there will be two modifications. CBIT-E will include additional in-session and out of session practice of exercises, called competing response. Treatment will include a screening visit, baseline assessment, 11 weeks (9 sessions) of CBIT-E, a post treatment assessment, and a three-month follow up assessment. Further, starting after session 3, there will be four 15-minute practice periods scheduled each week between sessions. During these practice periods, the child and therapist will meet over Microsoft Teams and the therapist will administer an enhanced reward task.
Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E)
Behavioral treatment for persistent tic disorders.
Waitlist Control (WLC)
These participants will not receive treatment during the 11-week period. Instead, they will be placed on a waitlist to receive standard CBIT following the end of the study period. The final assessment will be approximately 11 weeks after baseline.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E)
Behavioral treatment for persistent tic disorders.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* meets Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for TD or PTD
* at screening visit, a Parent Tic Questionnaire (PTQ) total score \> 18 and \< 60 OR \> 12 and \< 40 if persistent tic disorder (for total scores \> 60 on the PTQ, the research team will examine the patient's global functioning to determine participation appropriateness. The research team will consider if other treatments, such as medication, may be more appropriate for participants with PTQ total scores \> 60. If the participant is already taking tic medication, or tic medication has been unsuccessful in the past, then he/she may be considered for the study)
* at baseline visit, a Yale Global Tic Severity Score (YGTSS Total Score) \> 14 and \< 30 OR \> 10 and \< 20 if persistent tic disorder (for total scores \> 30 on the YGTSS, the research team will examine the patient's global functioning to determine participation appropriateness)
* no history of behavioral treatment for tics, including self-guided therapy programs for tics
* unmedicated or on stable medication for tics and other psychiatric disorder for at least 6 weeks, with no planned changes during study participation
* access to a personal computer (desktop or laptop) with a camera
* access to an Internet connection with a minimum speed of 5 megabytes per second (Mbps)
* fluent English speaker.
Exclusion Criteria
* T-Score \< 37 on the Wechsler Abbreviated Scale of Intelligence (WASI) - Vocabulary subtest
* T-Score \> 70 on the inattention or hyperactivity/impulsivity scales of the Conners 3-Parent Short (C 3-PS).
9 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Utah
OTHER
Marquette University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Marquette University
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HR-3837
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.